NEW YORK, Jan. 22, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on INO, INSM, ITCI, and JAZZ which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, January 19, 2018, the NASDAQ Composite ended the trading session
Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock finished Friday's session 1.39% higher at $4.39 with a total trading volume of 738,367 shares. The Company's shares have advanced 2.09% in the last month. The stock is trading below its 50-day moving average by 2.51%. Additionally, shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have a Relative Strength Index (RSI) of 48.20. Get the full research report on INO for free by clicking below at:www.wallstequities.com/registration/?symbol=INO
On Friday, shares in Bridgewater, New Jersey headquartered Insmed Inc. recorded a trading volume of 346,768 shares. The stock ended the session 0.75% lower at $29.28. The Company's shares have advanced 93.65% over the last twelve months. The stock is trading above its 200-day moving average by 30.47%. Moreover, shares of Insmed, which focuses on the development and commercialization of therapies for patients with rare diseases, have an RSI of 43.66.
On January 18th, 2018, research firm Credit Suisse initiated a 'Neutral' rating on the Company's stock, with a target price of $31 per share. Get access to our top-rated research, including the free report on INSM at:
New York headquartered Intra-Cellular Therapies Inc.'s shares closed the day 0.33% higher at $18.04. The stock recorded a trading volume of 190,051 shares. The Company's shares have gained 15.27% in the last month, 12.82% over the previous three months, and 30.25% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 14.69% and 27.86%, respectively. Additionally, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 64.43. Click here to subscribe for a free membership which welcomes you with our report on ITCI at: www.wallstequities.com/registration/?symbol=ITCI
Shares in Dublin, Ireland headquartered Jazz Pharmaceuticals PLC finished 0.37% lower at $148.70. The stock recorded a trading volume of 417,379 shares. The Company's shares have advanced 10.90% in the last month and 19.51% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 7.82% and 0.90%, respectively. Furthermore, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 67.36.
On January 03rd, 2018, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock, with a target price of $180 per share. Join our big investor community at Wall St. Equities today and get your free report on JAZZ at: www.wallstequities.com/registration/?symbol=JAZZ
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----inovio-pharma-insmed-intra-cellular-therapies-and-jazz-pharma-300585761.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All